Cytek Biosciences (CTKB) vs Standard BioTools (LAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cytek Biosciences (CTKB) has outperformed Standard BioTools (LAB) over the past year, gaining 40.9% versus a loss of 47.8%. Over five years, CTKB leads with a -77.8% price change compared with -87.3% for LAB. Cytek Biosciences is the larger company by market cap ($662.3 million vs $261.8 million), about 2.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTKB | LAB |
|---|---|---|
| Share price | $5.10 | $0.6668 |
| Market cap | $662.26M | $261.77M |
| 1-day change | -4.59% | -1.75% |
| YTD return | +5.74% | -46.98% |
| 1-year return | +40.90% | -47.79% |
| 5-year return | -77.81% | -87.29% |
| Forward P/E | 72.79 | — |
| EPS (TTM) | $-0.62 | $-0.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.21 | $1.72 |
| 52-week low | $3.31 | $0.63 |
| Distance from 52-week high | -17.95% | -61.23% |
| Analyst consensus | none | none |
| Avg. price target upside | +9.13% | +102.46% |
| Average volume | 1.04M | 1.57M |
| Shares outstanding | 129.98M | 392.58M |
| Employees | 682 | 385 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Cytek Biosciences is about 2.5 times larger than Standard BioTools by market value ($662.26M vs $261.77M).
- CTKB has outperformed LAB by 88.7 percentage points over the past year.
About Cytek Biosciences
CTKB stock →Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 682 employees
About Standard BioTools
LAB stock →Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.
Industrials · Biotechnology: Laboratory Analytical Instruments · 385 employees
CTKB vs LAB FAQ
Which is bigger, Cytek Biosciences or Standard BioTools?
Cytek Biosciences (CTKB) is larger, with a market capitalization of $662.26M compared with $261.77M for Standard BioTools (LAB).
Which stock has performed better over the past year, CTKB or LAB?
CTKB returned +40.90% over the past 12 months, compared with -47.79% for LAB (price return, excluding dividends). Past performance does not predict future results.
Are Cytek Biosciences and Standard BioTools in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.